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Abstract
Cystic	fibrosis	(CF)	is	the	most	common	recessively	autosomally	inherited	disorder	in	the	Caucasian	population.	It	is	incurable,	multi
-systemic	disease	with	progressive	course.	CF	is	caused	by	CFTR gene	mutation,	the	product	of	which	is	Cystic	Fibrosis	Transmem-
brane	Conductance	Regulator	(CFTR).	CF	patients	are	exposed	to	fat-soluble	vitamins	deficiency,	including	vitamin	D.	It	is	related	to	fat	
malabsorption	(caused	by	exacerbation	exocrine	pancreatic	insufficiency),	decreased	sun	exposure	(caused	by	receiving	antibiotics	
photophobia),	reduction	of	adipose	tissue	and	insufficient	supply	with	food.	The	discovery	of	vitamin	D	receptor	(VDR)	presence	out-
side	the	skeletal	system	allowed	to	conclude	that	vitamin	D	is	responsible	not	only	for	mineral	economy,	but	also	for	immunological	
processes,	respiratory	status,	intestinal	microflora	and	cystic	fibrosis-related	diabetes	(CFRD)	course.	
Basing	on	literature	data,	it	is	suggested	that	vitamin	D	plays	an	important	role	in	the	prevention	of	diseases	coexisting	with	CF.	The	
right	dosage	of	vitamin	D	allows	to	maintain	a better	lung	function	and	prevent	chronic	pulmonary	infections.	It	has	also	been	shown	
that	normal	levels	of	vitamin	D	may	be	important	in	increasing	the	chances	of	successful	lung	transplant	surgery.	Taking	the	wide	spec-
trum	of	vitamin	D	effects	into	account,	it	is	recommended	to	maintain	serum	concentrations	above	the	minimum	in	patients	with	CF.	
In	summary,	maintaining	the	proper	vitamin	D	levels	in	patients	with	CF	is	important	because	of	its	pleiotropic	effect.	It	can	be	
achieved	through	regular	monitoring	of	vitamin	D	levels	and	individual	supplementary	dose	for	each	patient.	
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Cystic fibrosis (CF) is the most common mo-
nogenic disease among the Caucasian population, 
inherited in an autosomal recessive manner [1–3]. 
This progressive disorder includes many organ 
systems and is characterized by high mortality at re-
latively young age. CF is caused by CFTR gene mu-
tation, the product of which is the CFTR protein, 
located on the top surfaces of the epithelial organs’ 
cells [2]. It is the ion channel protein, responsible 
for adjusting chloride and water flow through cell 
membranes [2, 3]. Each of over 2,000 known mu-
tations of the CFTR gene impairs the CFTR protein 
functions, resulting in overproduction of viscous, 
thick mucus, which accumulates in the organs of 
the respiratory and digestive systems [2].
The ones suffering from CF, besides other irre-
gularities related to nutrition, are exposed to a defi-
ciency in fat-soluble vitamins, including vitamin D. 
Its shortages (25(OH)D3 below 20 ng/ml) are observed 
among 22% of infants and the suboptimal level 
(25(OH)D3 20-30 ng/ml) — even among 90% of older 
children and young adults [4, 5]. Due to a prevalence 
of insufficient concentration of vitamin D in serum, 
it is recommended by the Cystic Fibrosis Foundation 
to examine its body resources annually, preferably 
in the winter season. If vitamin D’s saturation of 
the body during the reduced endogenous synthesis 
is appropriate, it leads to the conclusion that this 
condition will be maintained through the year while 
keeping an individual supplementation scheme [4].
The reasons for vitamin D shortages among 
patients with CF may include: fat absorption di-
sorders (caused by coexisting pancreatic exocrine 
insufficiency), low level of specific vitamin D 
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binding protein (DBP) and impaired hydrolysis to 
bioactive compounds in the liver, reduced expo-
sure to sunlight (the result of photosensitivity of 
used antibiotics), reduction of adipose tissue, as 
well as insufficient supply from food [4, 6–9].
Along with the life prolongation of patients 
suffering from CF, the co-occurrence of diseases 
characteristic of the adult population are observed 
more often. Available literature data indicate 
a positive correlation between age and severity of 
pulmonary disease and the level of advancement 
of skeletal changes and the vitamin D deficiency 
among these patients [9]. About 40% of children 
with CF also suffer from osteopenia, and 25% of 
adults — from osteoporosis [10]. This fat-soluble 
vitamin is necessary to maintain the proper con-
dition of the skeletal system, because it stimulates 
calcium and phosphorus absorption from the ga-
strointestinal tract and renal tubules, additionally 
affecting the mineralization of the bone matrix [7, 
11, 12]. It is also proved that the active form of 
vitamin D influences the activity of the calcium 
receptor gene (changing its expression), regula-
tes the secretion of parathyroid hormone (PTH) 
(inhibiting the proliferation of parathyroid cells), 
and — what is associated with it — reduces bone 
resorption [11]. It is particularly important in 
the context of the fact that the suboptimal level 
of vitamin D in CF patients’ serum may result 
in secondary hyperparathyroidism [7]. Mainta-
ining their bone system in a proper condition is 
essential. Every injury within it, immobilization 
and persistent pain may impair lung functioning, 
effective expectoration and clearing the airways, 
which ultimately leads to the progression of 
lung failure. It should be remembered that the 
reduction of bone mass is associated with muscle 
weakness, ribs and vertebrae fractures, as well as 
the formation of chest deformities, which additio-
nally promote the development of the disorders 
given above [9, 11].
The discovery of the presence of the vitamin 
D receptor (VDR) outside the bone cells leads to 
the conclusion that it is responsible not only for 
mineral metabolism, but also can affect other 
organs and their functions, including: respira-
tory system status, immunological processes, 
intestinal microflora condition and process of 
cystic fibrosis-related diabetes (CFRD) [6, 11, 
13, 14]. What is more, the status of vitamin D 
management plays an important role in the pre-
vention of disorders co-occurring with the basic 
disease. Supplying a proper supplementation 
dose (preferably a medicine) allows to protect 
structures and functions of the respiratory sys-
tem, especially by reducing the number of the 
sinuses, bronchi and lung infections. Therefore, 
it should be remembered that the most frequent 
reason for death among CF patients’ are respirato-
ry complications [15]. The Third National Health 
and Nutrition Examination Survey (NHANES III) 
researches revealed a positive correlation between 
a  low vitamin D derivative (25-hydroxyvitamin 
D) concentration in serum and acute pulmonary 
disease among patients with CF. It was observed 
that patients with the highest concentration of 
this vitamin in serum had 126ml higher forced 
expiratory volume (FEV1) and 173 ml higher 
forced vital capacity (FVC), in comparison with 
the group of patients with significant hypovi-
taminosis D. The protective effect of vitamin D 
in the course of chronic lung disease in CF is 
mainly discerned in its anti-inflammatory and 
immunomodulatory properties. The influence of 
vitamin D management in maintaining the proper 
level of proinflammatory cytokines, inhibition of 
oxidative stress development and homeostasis 
of protease — antiprotease system may result in 
collagen degradation and processes responsible 
for lung remodelling suppression [16]. The results 
of studies indicate that a single dose of 250,000 
IU of cholecalciferol to adults with CF who were 
admitted to the hospital due to exacerbations from 
the respiratory system, significantly reduced the 
necessity of next hospitalization during following 
six months, in comparison to those who were gi-
ven the placebo [8, 17]. Such a bolus of vitamin 
D instantly increased its concentration in serum, 
determining the patients’ life extension for at least 
a year, and also decreased the tumor necrosis fac-
tor (TNF-a) in plasma and significantly improved 
lung functioning [17].
The presence of dense, residual mucus, 
increased bacterial adherence to epithelial cells 
and impaired mucociliary clearance makes CF 
patients’ bronchi a perfect place for the develop-
ment of bacterial infections [18]. It is confirmed 
by epidemiological studies, which indicate that 
40-50% of CF infants undergo such an infection 
before the age of 6 months [19]. In response to the 
pathogen in the patient’s body, an inflammatory 
reaction arises, having a destructive effect on the 
lungs structure, much worse than the infection it-
self [18]. This immunologic response contributes 
to the intensified proinflammatory cytokines pro-
duction (e.g. IL-1b, IL-6, IL-8) and reduction of an-
ti-inflammatory interleukin (IL-10), which is a re-
ason for increased neutrophil influx to the infec-
ted area and respiratory system cells damage [19]. 
Vitamin D, which inhibits the secretion of TN-
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F-a (released under the influence of bacterial 
lipopolysaccharydes) and the expression of pro-
inflammatory cytokine genes, plays an essential 
role in this process. Considering immunological 
processes, there seems to be an important me-
chanism in which 1,25(OH)2D3 stimulates the 
expression of VDR, activating the secretion of 
cathelicidins — peptides with bactericidal effect 
on many microorganisms [6]. This form of vitamin 
D prevents, among others, colonization of Pseudo-
monas aeruginosa — a  common phenomenon 
which leads to impaired lung functioning and 
increased CF patients’ mortality [8].
Another potential point of vitamin D impact 
is the effect on carbohydrate metabolism disor-
ders among these patients. Cystic fibrosis-rela-
ted diabetes (CFRD) is one of the co-occurring 
diseases, which early diagnosed and adequately 
treated extends the patients’ survival time. The 
frequency of its diagnosis increases with age 
— from 5–8% among 5–10-year-old children to 
50% among adult patients [20]. The causes of 
CFRD are insulin shortages, caused by pancreatic 
b-cells dysfunction to allow the resistance of pe-
ripheral tissues to its action, severity of which is 
associated with glucocorticotherapy [13, 20, 21]. 
A specific phenomenon in this type of diabetes 
is the dynamic variability of glucose metabolism, 
depending on the presence of the infection, the 
functioning of respiratory and digestive systems 
and the nutritional status [22]. Although the vi-
tamin D’s influence on CFRD cannot be precisely 
defined, it is worth considering reports on other 
types of diabetes. Studies carried out among the 
populations of patients with type 1 diabetes have 
shown that the immunomodulatory effect of this 
vitamin helps to reduce the overactivity of the 
immune system against pancreatic b cells [23]. 
What is more, experiments conducted on the 
NOD mice have proved that long-term calcitriol 
supplementation results in a reduction of the pan-
creatic islet cells inflammation and diminishing 
the incidence of type 1 diabetes [24]. Adequate 
vitamin D intake in type 2 diabetes is also signi-
ficant. A decrease of 1,25(OH)2D3 concentration 
in serum is associated with b cells sensitivity 
to glycemic changes reduction and the insulin 
resistance of peripheral tissues increase, which 
increases the risk of developing this disease and 
results in hindering treatment [23].
The lung transplantation surgery, which is 
the only chance for some CF patients to improve 
the quality and length of their lives, is the situ-
ation when the proper level of vitamin D can play 
a crucial role [2]. The effect of calciferol is impor-
tant even before the moment of qualifying patient 
for the transplantation because contraindications 
to its implementation include considerable chest 
distortion or Pseudomonas aeruginosa infection 
(the carrier of this bacterium is considered in 
some transplantation centers). Furthermore, 
vitamin D deficiency might be a disqualifying 
criterion because 20% of CF patients suffer 
from CFRD, osteopenia, and osteoporosis after 
transplantation [15]. On the other hand, its 
proper concentration in serum may determine 
transplantation success because this fat-soluble 
vitamin affects antigen presenting cells (inclu-
ding dendritic cells) maturation, which weakens 
the T lymphocytes effect [25]. At the same time, 
studies carried out on rats have shown that calci-
triol suppresses the transplant rejection reaction 
more strongly than cyclosporine, simultaneously 
not increasing susceptibility to fungal and viral 
infections [26]. Lowry et al. [25] conducted expe-
riments assessing the effect of 25(OH)D deficiency 
in serum of lung transplant recipients’ clinical 
indicators. Their research revealed that such 
a condition during pre-transplantation period was 
associated with high risk of organ rejection and 
infection. What is important, this risk persisted 
if the level of hydroxyvitamin D did not improve 
in a year after surgery and had consequences in 
low patients survival. Moreover, similar results 
in the prognosis of patients with hypovitaminosis 
D were found after liver transplantations [27].
Retention of large amounts of sticky mucus 
impairs not only the lung, but also the intestines 
functioning, becoming the basis for excessive bac-
terial colonization, and consequently — intestinal 
microbiome disorders and the small intestinal 
bacterial overgrowth syndrome [28]. The proper 
functioning of the microflora in cystic fibrosis is 
additionally disturbed by constant exposure to an-
tibiotics used in respiratory tract infections [14]. 
This type of disorder impairs the complex nutritio-
nal compounds metabolism, disrupts energy 
balance and immunological homeostasis, which 
leads to malnutrition and increases susceptibility 
to pathogens and inflammatory reactions [29]. 
Studies, comparing the composition of the inte-
stinal microbiome among children with CF and 
healthy ones, revealed that in the first group, 
there was intestinal dysbiosis present from an 
early age which worsened over time. Besides, the 
loss of beneficial bacterial species was associated 
with the first lung exacerbation and Pseudomonas 
aeruginosa colonization [14]. The influence of 
vitamin D on the intestinal microflora is possi-
ble thanks to the VDR receptor, which plays an 
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important role in maintaining the integrity of the 
intestinal mucosa [13]. It is assumed that the role 
of calcitriol, in this case, is based on increasing 
of mucous membrane intercellular connections, 
which control its permeability and reduce the 
number of proinflammatory cytokines. Its defi-
ciency may enlarge the risk of intestinal damages 
and inflammation [14]. What makes keeping the 
normal state of the intestinal microbiome more 
important, are researches indicating the rela-
tionship between the type of bacteria colonizing 
intestine and lungs. Namely, a  large number of 
pathogens appear in the intestines before hitting 
the respiratory system [30].
And last but not least, hypovitaminosis D 
promotes depression. Research indicated a ne-
gative correlation between depressive symptoms 
and serum 25-hydroxivitamin D concentration. 
Its deficiency may result in an 8–14% increase 
in the incidence of depression and 50% higher 
risk of committing a suicide [31]. Groups of pa-
tients suffering from an incurable disease (such 
as cystic fibrosis) and requiring constant sup-
portive therapy, are particularly vulnerable to 
mood swings [32]. Recurrent states of symptoms’ 
exacerbation, fears associated with uncertain 
future, frequent hospitalizations and separation 
from family, as well as medication reluctance and 
associated with them side effects, make the effec-
tive antidepressant therapy difficult. Vitamin D 
supplementation, which is a primary prevention 
and supportive psychological treatment, could 
be a  significant element of multidisciplinary 
support of CF patients [31, 32]. Especially, that 
findings from a recent meta-analysis showed that 
subjects with clinically significant depression had 
a depressive symptoms reduction after adequate 
vitamin D supplementation [33].
Considering the wide spectrum of this vi-
tamin activity, it is recommended to keep the 
concentration of hydroxyvitamin D in serum at 
the level higher than minimum among patients 
suffering from CF. The ESPEN-ESPGHAN-ECFS 
guidelines indicate that it should exceed 20 ng/ml 
(50 nmol/l) [5], while the Cystic Fibrosis Founda-
tion sets a concentration of 30 ng/mL (75 nmol/l) 
as the minimum level [4]. Currently, European 
organizations recommend an individual vitamin 
D3 supplementation scheme, with initial and ma-
ximum dose depending on the patient’s age and 
condition (table 1) [4, 5]. The initial dose should 
be modified according to current hydroxyvitamin 
D concentration in serum, its dietary intake and 
the level of endogenous synthesis related to sun-
light exposure [5].
In conclusion, it can be certainly said that 
vitamin D plays a significant role in the course of 
cystic fibrosis. It exerts positive therapeutic effects 
not only on complications resulting from the basic 
disease but also on comorbidities. Maintaining its 
proper concentration in serum can be achieved by 
its regular monitoring, implementation of an in-
dividual supplementation scheme and — if there 
are no contraindications — sunbathing.
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